The General Hospital Corporation Research Management Division, doing business as Massachusetts General Hospital (MGH), was awarded a $140,130 Project Grant from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398). The award will fund research to elucidate the role of thiol reductive stress in the growth and metastasis of non-small cell lung cancer. The project aims to characterize how the activation of the NRF2 transcription factor, which is aberrantly expressed in many cancers, induces a reductive cellular state and disrupts mitochondrial metabolism, leading to vulnerabilities that can be therapeutically targeted. This foundational research will expand the understanding of redox regulation in cancer progression and identify potential new treatment strategies. The award term runs from March 1, 2025 to February 28, 2027.
Generated 3/18/25, 4:30 AM